Skip to main content
Download PDF
Download ePub

Burden of end-stage renal disease of undetermined etiology in Africa

Renal Replacement Therapy volume 9, Article number: 44 (2023) Cite this article

Abstract

In the last two decades, there have been increasing recognition of excess cases of end-stage renal disease (ESRD) requiring renal replacement therapy without common underlying causes (diabetes, hypertension, glomerulonephritis, or any identifiable cause) in many parts of low-to-middle income countries. ESRD of unknown etiology mainly affects young working-age adults and is a global health problem with substantial morbidity, mortality and disability. In this review, we provide a comprehensive overview of the burden and outcomes of treated ESRD attributable to unknown etiology in African countries. Estimates indicate that up to 71% of adults and up to 53% children on dialysis suffer from ESRD due to unknown etiology. ESRD of unknown etiology affects mostly the economically productive young adults, males and those from rural areas. ESRD due to unknown etiology carries an almost twofold risk of mortality compared to traditional ESRD causes and account for up to 55% of the renal medical admissions burden. This review confirms that treated ESRD due to unknown etiology is a major public health issue in Africa. Future studies are urgent need for better characterizing the regional causative factors as well as for developing proactive and comprehensive approaches to prevent and treat this under-recognized disease.

Introduction

Chronic kidney disease (CKD) is a major public health problem, and it can progress to end-stage renal disease (ESRD), requiring expensive therapies in the form of dialysis or renal transplantation for survival and has a major impact on healthcare costs, productivity and growth [1, 2]. Worldwide, the number of ESRD persons needing renal replacement therapy (RRT) is estimated between 4.902 and 9.701 million, with the majority occurring in low-to-middle income countries (LMICs) [3, 4]. It has also been estimated that as many as 3.2 million people die each year due to the inaccessibility of therapy, and thus, the majority of patients projected to reach ESRD in LMICs are unable to access RRT and die [3, 5]. Identification of underlying conditions of CKD leading to ESRD is of paramount importance to enable early diagnosis and treatment and thereby reduce the disease burden.

The global increase in ESRD is mainly attributed to the rise in prevalence of diabetes, hypertension, obesity and aging. In the last two decades, there have been increasing recognition of excess cases of ESRD requiring RRT without common underlying causes (diabetes, hypertension, glomerulonephritis, or any identifiable cause) in many parts of LMICs [6,7,8]. ESRD of unknown etiology mainly affects young working-age adults and is often fatal due to rapid disease progression and lack of dialysis or renal transplant options in the affected areas [7, 9]. It has resulted in thousands of deaths and placed an enormous burden on communities and healthcare systems, and is now recognized a serious public health concern requiring urgent action [6, 9, 10]. In Mexico, ESRD of unknown origin is the main cause of ESRD (54%) and accounts for the greatest global impact in terms of disability-adjusted life years [11, 12]. In El Salvador, 67% of new cases of ESRD were due to unknown etiology, and the condition is the leading cause of hospital deaths [13, 14]. Similar cases of unexplained ESRD have been reported in other Central and Latin American countries, regions within the Middle East and South Asia, and even in high-income countries with advanced diagnosis methods for kidney diseases [9, 15,16,17,18,19]. Across the reporting regions, the disease is attributed to environmental exposure to toxins and pollutants.

In Africa, CKD and consequent ESRD is increasingly recognized as a major public health threat mainly affecting young adults in their economically productive years, and seems to be of a more severe form than in developed countries [20, 21]. The prevalence of treated ESRD in Africa is relatively lower than incident CKD, which is at least 3–4 times more frequent than in developed countries, and this is likely due to late presentation (> 75% requiring dialysis at presentation and severely ill with co-morbidities) and limited access to RRT (only ~ 5% of patients with ESRD are able to get treatment for longer than 3 months) [5, 20,21,22,23]. ESRD care is especially challenging in Africa, with large numbers of ESRD patients, inadequate facilities and funding, and lack of renal registries [24, 25]. Even in wealthier country South Africa, the majority of people who develop ESRD are not offered RRT because of scarce resources, social factors related to poverty and established protocols which accept only young patients without significant comorbid disease [26, 27]. Thus, implementing cost-effective preventive interventions against ESRD is the only realistic solution for Africa [21, 25].

Data regarding the burden and etiology of ESRD are lacking in Africa and are unclear due to lack of renal registries in many African countries. Available literatures have established that chronic glomerulonephritis and hypertension are the principal causes of ESRD patients on renal therapy, together with diabetes and HIV [23, 28, 29]. However, selection bias may have played a significant role in these observations as most patients selected for RRT were considerably younger, affluent and have fewer comorbidities, which disadvantage the most vulnerable [5, 26,27,28, 30]. Accordingly, it is important to estimate the growing burden of treated ESRD due to other causes, to understand potential risk factors and highly vulnerable populations that lack specific diagnostic interventions and attentions and underrepresented in studies [31]. Also, such approaches can help identify regions as “hot spots” and have been a key first step in recognizing existing kidney disease of unknown cause epidemics in a given region [8].

In this review, we provide a comprehensive overview of the current evidence on the burden and outcomes of treated ESRD due to unknown etiology in Africa. The findings can be used to inform service providers, researchers, and regional and international agencies to a possible problem of treated ESRD of unknown cause in attempts to advocate for research, prevention, and treatment resources for kidney disease in general, and for unknown etiology of kidney disease in specific areas.

Methods

A literature search for relevant studies was performed using PubMed, Medline and the African Journals Online databases. Search terms used included: end-stage renal disease, ESRD, chronic renal failure, cause/etiology, unknown/undetermined/uncertain, renal replacement therapy, dialysis, AND Africa/country name in any combination in the title, abstract or MeSH terms. Reference lists from identified articles were also manually searched to identify any other relevant studies. Studies published in English language from the year 2000 onwards that contained data on treated ESRD due to unknown etiology in any African country and enrolled at least 50 adult participants were included. In general, ESRD of unknown etiology is a diagnosis of exclusion [8]. Accordingly, ESRD of unknown etiology refers to patients with ESRD or CKD stage 5 undergoing maintenance dialysis (hemodialysis or peritoneal dialysis), but without evidence of diabetes, hypertension, chronic glomerulonephritis, HIV, or any identifiable cause of ESRD (obstructive nephropathy, analgesic nephropathy, polycystic kidney disease, or other).

Results

ESRD of unknown etiology in adults

Published evidence on dialysis-treated ESRD due to unknown etiology in the last two decades was found for 24 African countries (Fig. 1) and those are divided into five regions for the clarity of present. Those are North Africa (n = 18 studies), West Africa (n = 13 studies), Central Africa (n = 4 studies), Southern Africa (n = 4 studies) and East Africa (n = 6 studies). A summary of the studies reviewed is presented in Table 1.

Fig. 1
figure 1

Prevalent numbers of patients with ESRD of unknown etiology, in reporting African countries by region (NA: North Africa; WA: West Africa; CA: Central Africa; SA: Southern Africa; EA: East Africa)

Full size image
Table 1 Summary of studies reported on dialysis-treated ESRD of undetermined etiology among adults
Full size table

In North Africa, the earliest reports on the occurrence of ESRD without a known underlying cause have been in the late 1980s [32]. In 2007–2011 reports of patients undergoing dialysis in Sudan, unknown etiology emerged as the leading cause of ESRD at 42.6–71.2% [33,34,35], while it accounted for 10.7% in a 2015 report [36]. According to the authors, the high rates of the ESRD cases with unknown etiology may reflect the lack of awareness of medical problems, lack of medical facilities in rural areas and/or delay in referral before arriving to the specialist physician. In Egypt, the etiology of ESRD patients on dialysis during the year 2006–2016 was dominated by unknown causes at 25–28% [37,38,39]. As of 2016–2020, estimates of Egyptian treated patients with ESRD of unknown etiology ranged from 13.7–19.5% [40,41,42]. In a 2012 study of 2417 prevalent dialysis patients in Libya, unknown etiology of ESRD was recorded at 7.3% [43]. Subsequent studies showed that unknown etiology accounts for 17.9–21.6% of treated ESRD patients [44,45,46]. In a 4-year Algerian study of 673 patients undergoing hemodialysis, 19.6% of ESRD cases were of unknown etiology [47]. The authors suggested that the prevalence of unknown ESRD etiology remains significant due to the late diagnosis of the disease and the low proportion of patients who can undertake renal biopsy (only 4%). In the 2021 studies of dialysis-treated patient in Tunisia, ESRD was of unknown etiology in 11% and 12.8% of cases [48, 49]. In Morocco, a study including 163 dialysis patients reported ESRD of unknown etiology in 42.2% of cases [50].

ESRD of unknown etiology reported countries in West Africa are Nigeria, Senegal, Gambia, Burkina Faso, Togo, Ivory Coast, Mauritania, Benin and Ghana. The first scientific evidence of unknown cause of chronic renal failure in Nigeria was reported in 1989 [51]. As of 2000, the reported prevalent numbers of patients with ESRD of unknown etiology in Nigeria ranged from 5.8 to 12% [52,53,54]. In one interesting study involving 127 Nigerians and 125 Caucasians, ESRD was of unknown etiology in 14% and 9% of cases, respectively [55]. The study noted that the prevalence, natural history and major etiological causes do vary from race to race and in location. In Senegal, dialysis-treated ESRD due to unknown etiology have been shown by two studies to be 14.5% and 20.3% [56, 57]. In the 2020 report of Gambian 170 patients under dialysis care over a 2-year period, unknown etiology was the second commonest cause of ESRD at 28.6%, following hypertension (42.9%) [58]. A study in Burkina Faso reported that 22.1% of 172 patients on chronic hemodialysis were due to ESRD of unknown etiology [59]. In a one-year study of 95 chronic hemodialysis patients in Togo, unknown etiology accounted for 10.5% of ESRD cases [60]. In a study of 255 patients on chronic hemodialysis during the year 2014–2020 in Ivory Coast, ESRD was of unknown etiology in 22.8% of cases [61]. In Mauritania, a study of 105 chronic hemodialysis patients showed that 36.3% of ESRD cases were due to unknown etiology [62]. In Benin, a study involving 131 chronic haemodialysis patients estimated ESRD of unknown etiology at 12.1% [63]. In Ghana, a prospective survey of 687 patients receiving dialysis estimated unknown etiology as the second common cause of ESRD at 28.5% [64].

In contrast, epidemiological data on treated ESRD due to unknown etiology in the other African regions is limited; this is likely due to low awareness of the condition. Reported ESRD of unknown etiology countries in Central Africa are Cameroon and Congo Republic–Brazzaville. In Cameroon, a study on the profile of 863 patients with ESRD covering a 10-year period reported ESRD due to unknown etiology in 14.7% of the cases [65]; while a study including 97 patients on hemodialysis estimated at 15.5% [66]. Another 10-year study of 661 Cameroonian haemodialysis patients showed an ESRD of unknown etiology of 16.9% [67]. In this study, the prevalent cases of ESRD due to unknown etiology ranged from 21.2% in 2002–2004 to 17.4% in 2011–2012, with a nadir at 9.0% in 2007–2008 and no significant difference. In Brazzaville, a 3-year study of 295 patients requiring emergency dialysis reported that 22.3% of the cases suffer from ESRD due to unknown etiology [68].

In Southern African countries, ESRD of unknown etiology cases are reported in South Africa and Zambia. In South Africa in 2016, a study involving 340 patients on chronic dialysis therapies over an 8-year period (2007–2014) showed the predomination of ESRD of unknown etiology at 45%, while stating late presentation play a role in the disease [69]. Subsequent studies showed that 29.4% of 6187 patients starting RRT and 11.6% of the 363 patients referred for RRT access were attributable to unknown etiology, and these are patients mostly present with advanced disease and small kidneys [70, 71]. In Zambia, a 4-year study including 154 patients who started chronic dialysis at the three largest public dialysis centers reported that 8% of the ESRD cases were of unknown etiology [72].

Unknown cause of ESRD also affects East African countries such as Ethiopian, Somalia, Burundi and Madagascar. In Ethiopia, 8% of the 436 patients on chronic hemodialysis were attributable to ESRD of unknown etiology [73], while a study involving 139 hemodialysis patients estimated unknown etiology as the second commonest cause of ESRD at 36.7% [74]. In Somalia, studies involving 208 and 127 patients undergoing haemodialysis estimated ESRD due to unknown etiology to account 5.7% and 24.4% of all causes, respectively [75, 76]. In a 4-year study of 65 patients on chronic hemodialysis in Burundi, ESRD of unknown etiology was reported in 21.7% of cases [77]. In a study involving 129 chronic hemodialysis patients from five dialysis centers in Antananarivo Madagascar, ESRD was of undetermined etiology in 10.5% of the cases [78].

Characteristics of affected population

The reported prevalent numbers of patients with ESRD of unknown etiology in the region vary by age, gender or residence status in a statistically significant manner (P < 0.05). Studies have shown that young adults are disproportionately affected by ESRD due to unknown etiology. In Sudan, the majority of the affected patients were younger than 40 years, twofold higher than in the older age groups [35, 36]. In Libya, ESRD due to unknown etiology was 2.3-fold higher in patients younger than 50 years than in patients 50 years or older [43], while in Somalia it was 3.4-fold higher [76]. In Cameroon, the affected patients were younger than 50 years (19.8% vs 9.8%) and mostly unemployed [65]. In Algeria, these rates were up to 1.9-fold higher in patients younger than 65 years [47]. Studies have also shown a preponderance of male patients with ESRD due to unknown etiology. In Egypt, prevalent ESRD because of unknown etiology was up to 5.4-fold higher in males than in females [37, 40]. In Libya, ESRD due to unknown etiology in males (12.2%) was 1.7-fold higher than in females (7.1%) [43].

Data from Egyptian studies revealed that treated ESRD due to unknown etiology was up to 5.4-fold higher in the rural than in the urban residents [37, 38]. People who live in rural areas were also at 2.4-fold higher risk of developing ESRD of unknown etiology than those living in urban areas [79]. The high rates of ESRD attributed to unknown etiology among rural communities might be ascribed to predisposition to farming with pesticids exposure and contaminated drinking water and food [37]. Indeed, people with a history of exposure to pesticides and drinking unsafe water were, respectively, reported to be at 2.1 and 2.8-fold risks of developing ESRD of unknown etiology [79]. According to the studies, people living in rural areas and those with lower socioeconomic status, lower educational status and limited health care facilities may have higher risk of etiology unknown ESRD that may be attributed to environmental factors. Other factor that provoke greater risk was use of different types of herbs for traditional treatments, which was higher in the rural areas [79].

Finally, patients with a family history of renal disease have been identified as the main group affected by ESRD with unknown etiology. In the Egyptian study, subjects with a family history of renal failure had a greater than threefold higher risk of ESRD of unknown etiology compared to those without such a family history [79]. In Libya, about 20.2–24.3% of the patients with ESRD of unknown etiology had a positive family history of renal failure [45, 46]. This suggests familial aggregation of the disease and that close relatives of ESRD of unknown etiology patients may benefit from directed screening and preventive efforts.

ESRD of unknown etiology in children

The prevalence of pediatric ESRD in Africa is on the rise and associated with poor outcome [22, 80, 81]. Primary causes of ESRD in children differ from those that are responsible for the adult onset of the disease. Although the spectrum of renal diseases in children in the continent may be similar to those of children in other regions of the world, there are unique features that bear material impact on the course of childhood ESRD in the continent [81]. Indeed, a recent review noted that in contrast to congenital anomalies of the kidneys and urinary tract as the leading cause of ESRD in children in Europe and North America, glomerular disorder is the frequently reported causes of childhood ESRD in the continent [82]. But, the lack of a comprehensive pediatric renal registry in most African countries makes it difficult to obtain accurate estimates about the underlying etiology of ESRD in children.

Data from a Libyan study of 76 children on maintenance dialysis over 11-years (2006–2016) rivaled that 52.6% of the ESRD cases were due to unknown etiology [83]. In Egypt, a study among children on regular hemodialysis for more than 1 year estimated an ESRD of unknown etiology of 23.3% [84]. In recent studies including 67 and 74 Egyptian children on maintenance hemodialysis, ESRD of unknown etiology accounted for 24% and 31.1% of all cases, respectively [85, 86]. In a 5-years study of 205 children with chronic renal failure at a tertiary pediatric nephrology in Sudan, unknown etiology was estimated at 39.1%, and patients present with small kidneys size [87]. The study further noted the pattern of late referrals and lack of intensive imaging modalities could play a role. In a study of Tunisian infants with ESRD who presented to the pediatric nephrology unit over 15 years (1998–2013), unknown etiology accounted for 12.5% of cases [88]. In Nigeria, a review of children on haemodialysis seen over a 3-year period reported ESRD of unknown etiology to be 20.0% [89]. In a study of South African children undergoing chronic dialysis, unknown ESRD etiology was reported in 3.7% of cases [90] (Table 2). If confirmed, these results would suggest the possibility that unknown etiology of ESRD may be occurring at an early age in the region.‬‬

Table 2 Summary of studies reported on dialysis-treated ESRD of undetermined etiology among children
Full size table

Outcome with ESRD of unknown etiology

Studies have shown that patients receiving RRT are at increased risk of mortality when the etiology of their ESRD is unknown, apparently because this group mainly includes patients who present late with advanced disease who have not had the benefit of pre-ESRD specialist care. In South Africa, compared to patients with hypertension as their ESRD cause, patients undergoing RRT with ESRD of unknown etiology have a twofold risk of mortality, while patients with diabetic ESRD did not have a significant difference in mortality [70]. In Cameroon, early mortality after the start of RRT was as high as 99% in patients with ESRD of unknown etiology compared to those with hypertensive ESRD [67]. Authors suggested that patients with ESRD of unknown etiology are more likely to carry a high burden of comorbidities, some of which on their own are highly fatal regardless of RRT. A mortality rates of 83% during a 1-year period have been also reported in Malawian children with ESRD of unclear etiology, and these were patients who presented with a much lower eGFR than other groups [91]. Additional studies are needed to increase our understanding of the increasing contribution of the problem in the African countries.

ESRD due to unknown etiology accounts for the largest fraction of the renal medical admissions burden. In Nigeria, a review of renal cases admitted over a 13-years period revealed that 51.6% of the patients were admitted on account of ESRD of unknown etiology [92]. A 5-year study of 1789 patients admitted to the nephrology and dialysis service in Brazzaville showed that 55.1% of admissions for ESRD were due to unknown etiology [93]. Of 712 chronic renal failure patients hospitalized in hemodialysis unit and cardiology service in Chad, 30.6% were of unknown etiology [94]. In a 6-year study of 384 chronic renal failure patients in adult internal medicine services in Senegal, 34.2% of the renal admissions were attributable to unknown etiology [95]. Other studies in Nigeria, Cameroon, Gambia and Ghana have also reported that 12.3–17.3% of all renal medical admissions and a mortality of 15% were attributable to ESRD of unknown etiology [52, 65, 96,97,98,99]. High medical admissions for ESRD due to unknown etiology adds an additional load onto the substantial healthcare burden and places a huge economic burden on the patients and families, including the cost of ESRD management. Indeed, patients who were hospitalized spent 50% more on their hemodialysis than not hospitalized patients [100]. Therefore, the presence of ESRD of unknown etiology identifies the subset of dialysis population in whom intervention might be most beneficial and economically attractive.

Despite the patients with ESRD of unknown etiology had the highest complexity in terms of the burden of comorbidities, rate of death and renal-related hospitalization, there is a dearth of published data regarding health-related quality of life of treated ESRD because of unknown etiology. The only study that estimated the quality of life associated with etiologies of ESRD demonstrated dialysis patient with ESRD of unknown etiology to have a significantly lower quality of life score compared to patient with diabetes and hypertension as their etiologies of ESRD [101].

Conclusion

Based on the existing evidence, it is well established that treated ESRD due to unknown etiology is a major public health issue in Africa, accounting for up to 71% of the prevalent cases of ESRD in adults and up to 53% in children. ESRD of unknown etiology is a major economic issue for the region, as it affects mostly young adults in their economically productive age, males and the poor in rural areas. The public health impact of ESRD due to unknown etiology is significant, with a substantial increase in mortality and a larger contribution to the renal admission burden, which might be catastrophic financial burden to the society and healthcare systems. ESRD of unknown etiology is therefore a condition that African countries cannot afford to ignore, and tthese results should attract policy attention and potentially form the basis to review current approach to ESRD care in Africa. There is an urgent need for epidemiological studies for better characterizing regional causative factors as well as for developing proactive and comprehensive approaches to prevent and treat this under-recognized fatal disease. Provision of a more comprehensive public health strategy and better care plan for this complex disease should be achieved by future international collaborative efforts and research.

Availability of data and materials

Not applicable.

Abbreviations

CKD:

Chronic kidney disease

ESRD:

End-stage renal disease

LMICs:

Low- to middle-income countries

RRT:

Renal replacement therapy

References

  1. Fox CS, Matsushita K, Woodward M, Bilo HJG, Chalmers J, Heerspink HJL, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet Lond Engl. 2012;380(9854):1662–73.

    Google Scholar 

  2. Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011;80(12):1258–70.

    PubMed  Google Scholar 

  3. Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. The Lancet. 2015;385(9981):1975–82.

    Google Scholar 

  4. Lv JC, Zhang LX. Prevalence and disease Burden of chronic kidney disease. Adv Exp Med Biol. 2019;1165:3–15.

    CAS  PubMed  Google Scholar 

  5. Anand S, Bitton A, Gaziano T. The gap between estimated incidence of end-stage renal disease and use of therapy. PLoS ONE. 2013;8(8):e72860.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Paidi G, Iroshani Jayarathna AI, Salibindla DBAMR, Amirthalingam J, Karpinska-Leydier K, Alshowaikh K, et al. Chronic kidney disease of unknown origin: a mysterious epidemic. Cureus. 2021;13(8):e17132.

    PubMed  PubMed Central  Google Scholar 

  7. Weaver VM, Fadrowski JJ, Jaar BG. Global dimensions of chronic kidney disease of unknown etiology (CKDu): a modern era environmental and/or occupational nephropathy? BMC Nephrol. 2015;16:145.

    PubMed  PubMed Central  Google Scholar 

  8. Caplin B, Yang CW, Anand S, Levin A, Madero M, Saran R, et al. The International Society of Nephrology’s International Consortium of Collaborators on Chronic Kidney Disease of Unknown Etiology: report of the working group on approaches to population-level detection strategies and recommendations for a minimum dataset. Kidney Int. 2019;95(1):4–10.

    PubMed  Google Scholar 

  9. Mahalingasivam V, Caplin B. Chronic kidney disease of undetermined aetiology: tens of thousands of premature deaths, yet too much remains unknown. Nephrol Dial Transplant. 2019;34(11):1839–41.

    PubMed  Google Scholar 

  10. Abraham G, Agarwal SK, Gowrishankar S, Vijayan M. Chronic kidney disease of unknown etiology: hotspots in India and other Asian countries. Semin Nephrol. 2019;39(3):272–7.

    PubMed  Google Scholar 

  11. Gutierrez-Peña M, Zuñiga-Macias L, Marin-Garcia R, Ovalle-Robles I, García-Díaz AL, Macías-Guzmán MJ, et al. High prevalence of end-stage renal disease of unknown origin in Aguascalientes Mexico: role of the registry of chronic kidney disease and renal biopsy in its approach and future directions. Clin Kidney J. 2021;14(4):1197–206.

    PubMed  PubMed Central  Google Scholar 

  12. Institute of Health Metrics and Evaluation. GBD Comare. IHME, University of Washington, Seattle. 2017.

  13. Trabanino RG, Aguilar R, Silva CR, Mercado MO, Merino RL. End-stage renal disease among patients in a referral hospital in El Salvador. Rev Panam Salud Publ. 2002;12(3):202–6.

    Google Scholar 

  14. Rodríguez M. Sounding the alarm on chronic kidney disease in farming communities: María Isabel Rodríguez MD. Minister of health, El Salvador. Interview by Conner Gorry. MEDICC Rev. 2013;15(3):8–10.

    PubMed  Google Scholar 

  15. Sarmento LR, Fernandes PFCBC, Pontes MX, Correia DBS, Chaves VCB, de Carvalho CFA, et al. Prevalence of clinically validated primary causes of end-stage renal disease (ESRD) in a State Capital in Northeastern Brazil. J Bras Nefrol. 2018;40(2):130–5.

    PubMed  PubMed Central  Google Scholar 

  16. Jha V. Current status of end-stage renal disease care in South Asia. Ethn Dis. 2009;19(1 Suppl 1):S1-27–32.

    PubMed  Google Scholar 

  17. Mousavi SSB, Soleimani A, Mousavi MB. Epidemiology of end-stage renal disease in Iran: a review article. Saudi J Kidney Dis Transplant. 2014;25(3):697–702.

    Google Scholar 

  18. Bragg-Gresham J, Morgenstern H, Shahinian V, Robinson B, Abbott K, Saran R. An analysis of hot spots of ESRD in the United States: Potential presence of CKD of unknown origin in the USA? Clin Nephrol. 2020;93(1):113–9.

    PubMed  Google Scholar 

  19. Kramer A, Stel V, Zoccali C, Heaf J, Ansell D, Grönhagen-Riska C, et al. An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006. Nephrol Dial Transplant. 2009;24(12):3557–66.

    PubMed  Google Scholar 

  20. Naicker S. End-stage renal disease in sub-Saharan Africa. Ethn Dis. 2009;19(1 Suppl 1):S1-13–5.

    PubMed  Google Scholar 

  21. Arogundade FA, Barsoum RS. CKD prevention in Sub-Saharan Africa: a call for governmental, nongovernmental, and community support. Am J Kidney Dis. 2008;51(3):515–23.

    PubMed  Google Scholar 

  22. Ashuntantang G, Osafo C, Olowu WA, Arogundade F, Niang A, Porter J, et al. Outcomes in adults and children with end-stage kidney disease requiring dialysis in sub-Saharan Africa: a systematic review. Lancet Glob Health. 2017;5(4):e408–17.

    PubMed  Google Scholar 

  23. Naicker S. End-stage renal disease in Sub-Saharan Africa. Kidney Int Suppl. 2013;3(2):161–3.

    Google Scholar 

  24. Swanepoel CR, Wearne N, Okpechi IG. Nephrology in Africa–not yet uhuru. Nat Rev Nephrol. 2013;9(10):610–22.

    PubMed  Google Scholar 

  25. Crosby L, Baker P, Hangoma P, Barasa E, Hamidi V, Chalkidou K. Dialysis in Africa: the need for evidence-informed decision making. Lancet Glob Health. 2020;8(4):e476–7.

    PubMed  PubMed Central  Google Scholar 

  26. Moosa MR, Kidd M. The dangers of rationing dialysis treatment: the dilemma facing a developing country. Kidney Int. 2006;70(6):1107–14.

    CAS  PubMed  Google Scholar 

  27. Kilonzo KG, Jones ESW, Okpechi IG, Wearne N, Barday Z, Swanepoel CR, et al. Disparities in dialysis allocation: an audit from the new South Africa. PLoS ONE. 2017;12(4):e0176041.

    PubMed  PubMed Central  Google Scholar 

  28. Naicker S. End-stage renal disease in sub-Saharan and South Africa. Kidney Int. 2003;63:S119–22.

    Google Scholar 

  29. Naicker S. Burden of end-stage renal disease in sub-Saharan Africa. Clin Nephrol. 2010;74(Suppl 1):S13-16.

    PubMed  Google Scholar 

  30. Faye FM, Audibert M. Ethical principles of renal therapy rationing in Senegal. Ren Replace Ther. 2022;8(1):24.

    Google Scholar 

  31. Ak B, Hi F, Ab F, Mr G, et al. Action plan for determining and monitoring the prevalence of chronic kidney disease. Kidney Int Suppl. 2017;7(2):63–70.

    Google Scholar 

  32. Osman EM, Abboud OI, Danielson BG. Chronic renal failure in Khartoum. Sudan Ups J Med Sci. 1987;92(1):65–73.

    CAS  PubMed  Google Scholar 

  33. El-Amin HH, Osman EM, Mekki MO, Abdelraheem MB, Ismail MO, Yousif MEA, et al. Hepatitis C virus infection in hemodialysis patients in Sudan: two centers’ report. Saudi J Kidney Dis Transplant. 2007;18(1):101–6.

    CAS  Google Scholar 

  34. Elamin S, Obeid W, Abu-Aisha H. Renal replacement therapy in Sudan, 2009. Arab J Nephrol Transplant. 2010;3(2):31–6.

    Google Scholar 

  35. Elsharif ME, Elsharif EG. Causes of end-stage renal disease in Sudan: a single-center experience. Saudi J Kidney Dis Transplant. 2011;22(2):373–6.

    Google Scholar 

  36. Banaga ASI, Mohammed EB, Siddig RM, Salama DE, Elbashir SB, Khojali MO, et al. Causes of end stage renal failure among haemodialysis patients in Khartoum State/Sudan. BMC Res Notes. 2015;8:502.

    PubMed  PubMed Central  Google Scholar 

  37. El-Minshawy O, Kamel E. Renal replacement therapy and increased risk of cardiovascular disease In El-Minia Governorate, Upper Egypt. Egypt J Hosp Med. 2006;22(1):29–38.

    Google Scholar 

  38. El Minshawy O. End-stage renal disease in the El-Minia Governorate, upper Egypt: an epidemiological study. Saudi J Kidney Dis Transplant. 2011;22(5):1048–54.

    Google Scholar 

  39. El-Arbagy AR, Yassin YS, Boshra BN. Study of prevalence of end-stage renal disease in Assiut governorate, upper Egypt. Menoufia Med J. 2016;29(2):222.

    Google Scholar 

  40. Ghonemy TA, Farag SE, Soliman SA, El-okely A, El-hendy Y. Epidemiology and risk factors of chronic kidney disease in the El-Sharkia Governorate, Egypt. Saudi J Kidney Dis Transplant. 2016;27(1):111–7.

    Google Scholar 

  41. Hafez MZE, Ali OM, Kassem SA, Gafaar HA. Epidemiology and risk factors of end stage renal disease in Aswan Governorate, Upper Egypt. Egypt J Hosp Med. 2019;74(6):1298–306.

    Google Scholar 

  42. Ahmed H, Zahran A, Issawi R. Prevalence and etiology of end-stage renal disease patients on maintenance hemodialysis. Menoufia Med J. 2020;33:766–71.

    Google Scholar 

  43. Alashek WA, McIntyre CW, Taal MW. Epidemiology and aetiology of dialysis-treated end-stage kidney disease in Libya. BMC Nephrol. 2012;13:33.

    PubMed  PubMed Central  Google Scholar 

  44. Gusbi E, Abrahem AF, Elfituri A, Eltaib F, Benbubaker WM, Alhudiri IM, et al. Causes of end-stage renal disease among hemodialysis patients in Libya: A multicenter cross-sectional study. Libyan J Med Sci. 2021;5(4):139.

    Google Scholar 

  45. Elamouri J. Family history in patients with end-stage renal disease on hemodialysis in Tripoli, Libya. Ibnosina J Med Biomed Sci. 2021;13(1):14–14.

    Google Scholar 

  46. Alsaeiti K, Hamedh M, Albarasi S, Alagoory M, Isawi Y, Benali S, et al. Current clinical situation of hemodialysis patients in nephrology center, Benghazi, Libya. J Egypt Soc Nephrol Transpl. 2021;21:43–7.

    Google Scholar 

  47. Berkache K, Bengharez Z, Poitier B, Ouabdesslam D, Guerinik A, Amrane M. End-stage kidney disease in Sidi Bel Abbes, Algeria: epidemiological profile of hemodialysis patients from 2015 to 2018. Clin Epidemiol Glob Health. 2021;12: 100808.

    CAS  Google Scholar 

  48. Mesbahi T, Barbouch S, Najjar M, Fattoum S, Jebali H, Trabelsi R, et al. End-stage renal disease at dialysis initiation: Epidemiology and mortality risks during the first year of hemodialysis. Saudi J Kidney Dis Transplant. 2021;32(5):1407–17.

    Google Scholar 

  49. Salem MB, Ayed A, Taieb SK, Handous I, Saleh MB, Hamouda M, et al. Peritoneal dialysis in Tunisia: complications, technique and patient’s survival (twenty-seven years of experience in a single center). Pan Afr Med J. 2021;39:179.

    PubMed  PubMed Central  Google Scholar 

  50. Abdelaali B, Omar M, Taoufik D, Samir A, Saad M. Hepatitis C viral prevalence and seroconversion in Moroccan hemodialysis units: Eight year follow up. J Med Diagn Methods. 2013;2:14.

    Google Scholar 

  51. Akinsola W, Odesanmi WO, Ogunniyi JO, Ladipo GO. Diseases causing chronic renal failure in Nigerians—a prospective study of 100 cases. Afr J Med Med Sci. 1989;18(2):131–7.

    CAS  PubMed  Google Scholar 

  52. Arogundade FA, Sanusi AA, Hassan MO, Akinsola A. The pattern, clinical characteristics and outcome of ESRD in Ile-Ife, Nigeria: is there a change in trend? Afr Health Sci. 2011;11(4):594–601.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Okunola Y, Ayodele O, Akinwusi P, Gbadegesin B, Oluyombo R. Haemodialysis practice in a resource-limited setting in the tropics. Ghana Med J. 2013;47(1):4–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Amira C, Lesi O. Seroprevalence of hepatitis B and C infection among Nigerian subjects with chronic kidney disease. J Clin Sci. 2017;14(2):58–60.

    Google Scholar 

  55. Chijioke A, Adeniyi AB. End stage renal disease: racial differences. Orient J Med. 2003;15(1):24–31.

    Google Scholar 

  56. Niang A, Cisse MM, Mahmoud SMOM, Lemrabott ATO, Ka EHF, Diouf B. Pilot experience in senegal with peritoneal dialysis for end-stage renal disease. Perit Dial Int. 2014;34(5):539–43.

    PubMed  PubMed Central  Google Scholar 

  57. Abderraman GM, Cisse MM, Mouhatta O. Evaluation of the phosphocalcic profile of chronic hemodialysis patients in Senegal. Int J Nephrol Kidney Fail. 2018;4(4).

  58. Sanyang Y, Sambou M. Mortality rate in hemodialysis patient in Edward Francis Small Teaching Hospital the Gambia. Int J Afr Nurs Sci. 2020;13:100262.

    Google Scholar 

  59. Gérard C, Augustin DS, Roger KA, Aïda LMH, Gaoussou S, Hien KM, et al. Epidemiological profile of chronic hemodialysis patients in Ouagadougou. Open J Nephrol. 2016;6(2):29–36.

    Google Scholar 

  60. Salou M, Sabi KA, Tevi A, Ekouevi K, Dossim S, Lack F, et al. Prevalence and factors associated with Hepatitis B virus surface antigen and Human Immunodeficiency virus antibodies in chronic hemodialysis patients followed-up in Lomé. Togo Open J Med Microbiol. 2019;9(1):16–27.

    Google Scholar 

  61. Mélanie TW, Anastasie WM, Marie KCZR, Jonathan KK, Yannick G, Romuald B, et al. Epidemiological profile on chronic hemodialysis patients in semi-urban city in Ivory Coast. J Nephrol Ther. 2022;12(10):416.

    Google Scholar 

  62. Salem MLO, Bellamech ME, Mohamed MS, Mohamed GS. Prevalence and clinico-biological characteristics of viral Hepatitis B and C in chronic hemodialysis patients at the National Hospital Center of Nouakchott-Mauritania. Int J Clin Case Rep Rev. 2022;11(4):1–10.

    Google Scholar 

  63. Ka EF, Vigan J, Lemrabott AT, Zohoun NE, Cissé MM, Ahoui S, et al. Quality of life of chronic haemodialytic patients at Cotonou Teaching Hospital (BENIN). Open J Nephrol. 2014;4(4):131–41.

    Google Scholar 

  64. Boima V, Tannor EK, Osafo C, Awuku YA, Mate-Kole M, Davids MR, et al. The Ghana Renal Registry—a first annual report. Afr J Nephrol. 2021;24(1):19–24.

    Google Scholar 

  65. Halle MP, Takongue C, Kengne AP, Kaze FF, Ngu KB. Epidemiological profile of patients with end stage renal disease in a referral hospital in Cameroon. BMC Nephrol. 2015;16:59.

    PubMed  PubMed Central  Google Scholar 

  66. Halle MP, Choukem SP, Kaze FF, Ashuntantang G, Tchamago V, Mboue-Djieka Y, et al. Hepatitis B, Hepatitis C, and Human Immunedeficiency virus seroconversion positivity rates and their potential risk factors among patients on maintenance hemodialysis in Cameroon. Iran J Kidney Dis. 2016;10(5):304–9.

    PubMed  Google Scholar 

  67. Halle MP, Ashuntantang G, Kaze FF, Takongue C, Kengne AP. Fatal outcomes among patients on maintenance haemodialysis in sub-Saharan Africa: a 10-year audit from the Douala General Hospital in Cameroon. BMC Nephrol. 2016;17(1):165.

    PubMed  PubMed Central  Google Scholar 

  68. Sinomono DTE, Loumingou R, Koumou GCG, Mahoungou GH, Mobengo JL. Chronic renal failure in the Brazzaville University Hospital Center: epidemiological, clinical and evolutionary aspects. Saudi J Kidney Dis Transplant. 2021;32(5):1450–5.

    Google Scholar 

  69. Isla RAT, Ameh OI, Mapiye D, Swanepoel CR, Bello AK, Ratsela AR, et al. Baseline predictors of mortality among predominantly rural-dwelling end-stage renal disease patients on chronic dialysis therapies in Limpopo, South Africa. PLoS ONE. 2016;11(6):e0156642.

    Google Scholar 

  70. Jardine T, Wong E, Steenkamp R, Caskey FJ, Davids MR. Survival of South African patients on renal replacement therapy. Clin Kidney J. 2020;13(5):782–90.

    PubMed  PubMed Central  Google Scholar 

  71. Molaoa TT, Bisiwe FB, Ndlovu KC. End-stage kidney disease and rationing of kidney replacement therapy in the free state province, South Africa: a retrospective study. BMC Nephrol. 2021;22(1):174.

    PubMed  PubMed Central  Google Scholar 

  72. Banda J, Bulaya T, Mweemba A, Mweene M, Suwilanji N, Natasha C, et al. Early mortality in patients with kidney failure starting chronic dialysis in Zambia: a retrospective cohort analysis. Afr J Nephrol. 2022;25(1):3–7.

    Google Scholar 

  73. Workie SG, Zewale TA, Wassie GT, Belew MA, Abeje ED. Survival and predictors of mortality among chronic kidney disease patients on hemodialysis in Amhara region, Ethiopia, 2021. BMC Nephrol. 2022;23(1):193.

    PubMed  PubMed Central  Google Scholar 

  74. Desta BZ, Dadi AF, Derseh BT. Mortality in hemodialysis patients in Ethiopia: a retrospective follow-up study in three centers. BMC Nephrol. 2023;24(1):3.

    PubMed  PubMed Central  Google Scholar 

  75. Mohamed AH, Jeele MOO. Epidemiology of end-stage renal disease in Mogadishu, Somalia: first report at a tertiary care hospital. Int J Gen Med. 2022;15:6259–67.

    PubMed  PubMed Central  Google Scholar 

  76. Rage HI, Jha PK, Kahin A, Hersi S, Mohamed A, Elmi M. Causes of end stage renal disease among patients undergoing hemodialysis in Somalia: a multi-center Stud. Res Sq. 2022.

  77. Nyandwi J, Ndirahisha E, Manirakiza S, Barasukana P. SAT-038 Hemodialysis in Burundi: data and challenges. Kidney Int Rep. 2019;4(7):S19-20.

    Google Scholar 

  78. Rakotoarisaona MF, Sendrasoa FA, Andrianarison M, Raharolahy O, Razanakoto NH, Sata M, et al. Cutaneous manifestations in chronic hemodialysis patients in antananarivo madagascar. Int J Clin Dermatol. 2022;5(1):6.

    Google Scholar 

  79. Kamel E, El-Minshawy O. Environmental factors incriminated in the development of end stage renal disease in El-Minia Governorate, Upper Egypt. Nephro-Urol Mon. 2010;2(3):431–7.

    Google Scholar 

  80. Asinobi AO, Ademola AD, Ogunkunle OO, Mott SA. Paediatric end-stage renal disease in a tertiary hospital in South West Nigeria. BMC Nephrol. 2014;15:25.

    PubMed  PubMed Central  Google Scholar 

  81. Ladapo TA, Esezobor CI, Lesi FE. Pediatric kidney diseases in an African country: prevalence, spectrum and outcome. Saudi J Kidney Dis Transplant. 2014;25(5):1110–6.

    Google Scholar 

  82. Esezobor CI, Alakaloko A, Admani B, Ellidir R, Nourse P, McCulloch M. Paediatric nephrology in Africa. Curr Pediatr Rep. 2021;9(4):1–8.

    Google Scholar 

  83. Sauod EBB, Aklifa A. End-stage renal disease in children on maintenance dialysis in Benghazi, Libya. Ibnosina J Med Biomed Sci. 2017;9:128–31.

    Google Scholar 

  84. Hasan MF, Rabeea MM, Hassan HA, Abd-Elkader AA, Elzamarany EHM. Neurophysiologic study in children with end stage renal disease on regular hemodialysis. Al-Azhar Int Med J. 2021;2(12):28–34.

    Google Scholar 

  85. Moawad H, Etewa S, Mohammad S, Neemat- Allah M, Degheili J, Sarhan M. Seropositivity of toxoplasmosis among hemodialysis children patients at Zagazig University Pediatrics Hospital, Egypt. Parasitol United J. 2022;15(1):53–9.

    Google Scholar 

  86. Youssef DM, El-Shal AS, Elbehidy RM, Fouda MA, Shalaby SM, El Hawy LL, et al. Hepatitis B immunization status in children with chronic kidney disease: experience at a single center, Egypt. J Clin Med. 2023;12(5):1864.

    CAS  PubMed  PubMed Central  Google Scholar 

  87. Ali ETMA, Abdelraheem MB, Mohamed RM, Hassan EG, Watson AR. Chronic renal failure in Sudanese children: aetiology and outcomes. Pediatr Nephrol Berl Ger. 2009;24(2):349–53.

    Google Scholar 

  88. Jellouli M, Boussetta A, Abidi K, Hammi Y, Zarrouk C, Gargah T. End-stage renal disease in Tunisian infants: Etiology and outcome. Indian J Nephrol. 2016;26(6):405–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  89. Obiagwu PN, Abdul A, Abubakar ND. Haemodialysis treatment among children with kidney failure in North-Western Nigeria: a three-year review. Trop J Nephrol. 2012;7(1 & 2):33–7.

    Google Scholar 

  90. Obiagwu PN, Sangweni B, Moonsamy G, Khumalo T, Levy C. Health-related quality of life in children and adolescents with end-stage renal disease receiving dialysis in Johannesburg. South Afr J Child Health. 2018;12(2):58–62.

    Google Scholar 

  91. Mwanza ZV, McCulloch M, Drayson M, Plant T, Milford DV, Dreyer G. Proteinuric kidney disease in children at Queen Elizabeth Central Hospital, Malawi. BMC Nephrol. 2018;19(1):21.

    PubMed  PubMed Central  Google Scholar 

  92. Ulasi II, Ijoma CK. The enormity of chronic kidney disease in Nigeria: the situation in a teaching hospital in South-East Nigeria. J Trop Med. 2010;2010: 501957.

    PubMed  PubMed Central  Google Scholar 

  93. Sinomono DTE, Sedan GNO, Mahoungou GH, Ngabe EPG, Loumingou RM, Ellenga-Mbolla B, et al. Epidemiological clinical profile of chronic kidney disease in adults under 50 at the University Hospital of Brazzaville. Open J Nephrol. 2021;11(3):358–69.

    Google Scholar 

  94. Abderraman GM, Hamat I, Tondi ZMM, Lemrabott AT, Faye M, Moustapha CM, et al. Hyperuricemia in patients with chronic renal failure in the general hospital of National Reference of N’Djamena (Chad). Open J Nephrol. 2017;7(1):9–18.

    CAS  Google Scholar 

  95. Diouf B, Ka EF, Niang A, Diouf ML, Mbengue M, Diop TM. Etiologies of chronic renal insufficiency in a adult internal medicine service in Dakar. Dakar Med. 2000;45(1):62–5.

    CAS  PubMed  Google Scholar 

  96. Kaze FF, Ekokobe FE, Halle MP, Fouda H, Menanga AP, Ashuntantang G. The clinical pattern of renal diseases in the nephrology in-patient unit of the Yaounde General Hospital in Cameroon: a five-year audit. Pan Afr Med J. 2015;21:205.

    PubMed  PubMed Central  Google Scholar 

  97. Jatta JW, Serwaa D, Ayepola F, Oudraogo JCRP. Characterization of patients with chronic kidney disease admitted at Edward Francis Small Teaching Hospital in the Gambia: a descriptive cross-sectional study. PAMJ One Health. 2020;2(15).

  98. Amoako YA, Laryea DO, Bedu-Addo G, Andoh H, Awuku YA. Clinical and demographic characteristics of chronic kidney disease patients in a tertiary facility in Ghana. Pan Afr Med J. 2014;18:274.

    PubMed  PubMed Central  Google Scholar 

  99. Wachukwu CM, Emem-Chioma PC, Wokoma FS, Oko-Jaja RI. Pattern and outcome of renal admissions at the University of Port Harcourt Teaching Hospital, Nigeria: a 4 years review. Ann Afr Med. 2016;15(2):63–8.

    PubMed  PubMed Central  Google Scholar 

  100. Toure A, Balde M, Diallo A, Camara S, Soumah A, Sall AO, et al. The direct cost of dialysis supported by families for patients with chronic renal failure in Ouagadougou (Burkina Faso). BMC Nephrol. 2022;23(1):222.

    PubMed  PubMed Central  Google Scholar 

  101. Sambou M, Bah HT, Sanyang Y. Quality of life of patients undergoing haemodialysis at Edward Francis Small Teaching Hospital. Int J Sci Technol Res Arch. 2022;3(2):196–202.

    Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Department of Clinical Laboratory Science, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia

    Temesgen Fiseha

  2. School of Public Health, Faculty of Medicine, The University of Queensland, Brisbane, Australia

    Nicholas J. Osborne

  3. School of Population Health, University of New South Wales, Sydney, NSW, 2052, Australia

    Nicholas J. Osborne

  4. European Centre for Environment and Human Health (ECEHH), University of Exeter Medical School, Knowledge Spa, Royal Cornwall Hospital, Truro, Cornwall, TR1 3HD, UK

    Nicholas J. Osborne

Authors
  1. Temesgen Fiseha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicholas J. Osborne
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

TF and NJO were involved in conceptualization, methodology, data curation (systematic database search) and writing–original draft and review and editing. The manuscript was finalized and prepared for submission by TF. All authors read and approved the final version of the paper.

Corresponding author

Correspondence to Temesgen Fiseha.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fiseha, T., Osborne, N.J. Burden of end-stage renal disease of undetermined etiology in Africa. Ren Replace Ther 9, 44 (2023). https://doi.org/10.1186/s41100-023-00497-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s41100-023-00497-w

Keywords

Renal Replacement Therapy

ISSN: 2059-1381

Contact us